Supernus Patent-Cliff Exposure & CMS Drug Spending Portfolio

Supernus (US): 4 reconciled FDA prescription therapies (31.7% 2025 to 2030 cliff risk), $426.6M 2024 CMS Part D & Medicaid spend, and 30 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure31.7%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$426.6M
2024 Medicare Part D Spend$153.0M
2024 Medicaid Spend$273.6M
California HCAI SB 17 Filings30 WAC filings (max 19.2% 2-yr change)